Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Pilot Study of Free and Cued Selective Reminding Test in a Lebanese Sample: A study on Normal, MCI and AD patients
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (5:30 PM-6:30 PM)
The Free and Cued Selective Reminding Test (FCSRT) is a memory test that assesses learning and acquisition, by providing category cues in the learning process. It is a reliable tool for the assessment of episodic memory, used to differentiate between Alzheimer Disease (AD) patients and patients with Mild Cognitive Impairment (MCI).
 Our aim was to assess the suitability of the use of a culturally adapted version of the FCSRT in the Lebanese population diagnosed with MCI and AD through comparing between three groups of subjects – normal, MCI and AD. 
Subjects were recruited based on their visit, for a regular memory consultation in a memory clinic in Beirut. All of them completed the test conducted by a clinician.
Results: The sample included 3 populations divided as follows: 29 normal, 22 MCI and 24 AD subjects. Our results showed that the adapted Arabic version of the FCSRT is discriminating between the 3 populations with a major significant difference between the healthy and AD population. The overall profile on the FCSRT revealed that normal subjects had the highest scores followed by MCI and then AD subjects. The learning curve of normal controls and MCI patients is ascendant while AD subjects exhibit a depressed learning curve.

This study represents a novel contribution regarding the adequacy of the Arabic version of the FCSRT in terms of distinguishing between AD and non-AD subjects. Besides, it gives new possibilities concerning the use of the FCSRT in the evaluation of the spectrum of memory disorders.


Fadi K. Abou-Mrad, MD, PhD, FAAN (St Charles Hospital-Fayadieh)
Dr. Abou-Mrad has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Gordon J. Chelune, PhD (University of Utah) The institution of an immediate family member of Dr. Chelune has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor & Francis. Dr. Chelune has stock in Centruy Therapeutics, Inc. The institution of Dr. Chelune has received research support from NIA. Dr. Chelune has received intellectual property interests from a discovery or technology relating to health care. Dr. Chelune has received publishing royalties from a publication relating to health care.
No disclosure on file